Soligenix, Inc. (LON:0A6I)
1.520
-0.060 (-3.80%)
At close: Dec 3, 2025
Soligenix Employees
As of December 31, 2024, Soligenix had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-554.06K GBP
Market Cap
12.19M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | 1 | 6.67% |
| Dec 31, 2023 | 15 | 0 | - |
| Dec 31, 2022 | 15 | 0 | - |
| Dec 31, 2021 | 15 | -3 | -16.67% |
| Dec 31, 2020 | 18 | 2 | 12.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HSBC Holdings | 211,304 |
| Unilever | 115,964 |
| BP p.l.c. | 100,500 |
| Shell | 96,000 |
| AstraZeneca | 94,300 |
| Barclays | 93,000 |
| GSK plc | 68,629 |
| Lloyds Banking Group | 61,228 |
Soligenix News
- 16 days ago - Soligenix (SNGX) Completes Key Enrollment for Phase 3 Study on CTCL Treatment - GuruFocus
- 16 days ago - Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 4 weeks ago - Soligenix GAAP EPS of -$0.58 beats by $0.05 - Seeking Alpha
- 4 weeks ago - Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results - PRNewsWire
- 7 weeks ago - Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Soligenix (SNGX) Advances Phase 3 CTCL Study with Positive Safety Review - GuruFocus
- 2 months ago - Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Insider Buying: Christopher Schaber Acquires Shares of Soligenix Inc (SNGX) - GuruFocus